Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
23.17 CNY +0.09% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +0.30% -7.43%
May. 27 Shanghai Fosun Pharmaceutical (Group)'s Investigational New Drug Application Accepted by NMPA MT
May. 15 Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shanghai Fosun Pharmaceutical (Group)'s Investigational New Drug Application Accepted by NMPA
MT
Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment
MT
China Approves Clinical Trials For Breast Cancer Drugs
MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug
MT
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets
MT
Fosun Pharma's Q1 Profit Slumps 38%
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator
MT
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
MT
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator
MT
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs
MT
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners
CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.